Actuate Therapeutics (ACTU)
Develops elraglusib, a GSK-3β inhibitor, for metastatic pancreatic cancer.
$1.37
Pre-market+0.07 (+4.98%)
At close$1.31(−15.26%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions61 holders · as of Mar 31, 2026 | 57.71% | 13.86M shares | |
| Insiders5 holders · as of Aug 14, 2026 | 93.36% | 22.42M shares | |
| Strategic holders1 holder · as of Jun 30, 2025 | 0.82% | 196.4K shares | |
| Adds to | 151.89% |
24.01M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 151.89%; nothing is left for Other.
Institutions13F, as of Mar 31, 2026
61 holders · 13.86M shares · 23 new positions · 42 increased · 10 reduced · 6 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Bios Capital Management, LP | 10.05M | 41.85% | 0 | May 13, 2026 |
| Voss Capital, LLC | 1.73M | 7.18% | +425.0K | May 15, 2026 |
| BlackRock, Inc. | 427.2K | 1.78% | −4.9K | May 13, 2026 |
| Vanguard Capital Management LLC | 400.5K | 1.67% | +400.5Knew | May 15, 2026 |
| Geode Capital Management, LLC | 228.3K | 0.95% | +20.6K | May 15, 2026 |
| Connective Capital Management, LLC | 113.3K | 0.47% | +113.3Knew | May 13, 2026 |
| Palogic Value Management, L.P. | 100.0K | 0.42% | +100.0Knew | May 15, 2026 |
| Northern Trust Corp | 97.9K | 0.41% | −3.6K | May 14, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Aaron G.L. Fletcherincl. Cavu Advisors, LLC, Bios Capital Management, LP +21 more | 49.80% | 10.27M | 13D | Jun 30, 2025 ↗ |
| Voss Capital, LP | 7.70% | 1.81M | 13G | Apr 22, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jan 5, 2026 | Todd S. Thomsondirector, 10 percent owner: | Sale | 280,000 | $5.80 | 904,795 |
CongressHouse and Senate disclosures
Not reported.